Stuver, R., Shah, G. L., Korde, N. S., Roeker, L. E., Mato, A. R., Batlevi, C. L., . . . Vardhana, S. A. (2022). Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer cell, 40(6), 590. https://doi.org/10.1016/j.ccell.2022.05.007
Chicago-Zitierstil (17. Ausg.)Stuver, Robert, et al. "Activity of AZD7442 (tixagevimab-cilgavimab) Against Omicron SARS-CoV-2 in Patients with Hematologic Malignancies." Cancer Cell 40, no. 6 (2022): 590. https://doi.org/10.1016/j.ccell.2022.05.007.
MLA-Zitierstil (9. Ausg.)Stuver, Robert, et al. "Activity of AZD7442 (tixagevimab-cilgavimab) Against Omicron SARS-CoV-2 in Patients with Hematologic Malignancies." Cancer Cell, vol. 40, no. 6, 2022, p. 590, https://doi.org/10.1016/j.ccell.2022.05.007.